Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 766 AL 780

A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease

Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJ, Chazot P, Lees G, Ballard C.

Dement Geriatr Cogn Disord. 2011;31(2):158-64. doi: 10.1159/000324438. Epub 2011 Feb 19.

DTI studies in patients with Alzheimer's disease, mild cognitive impairment, or normal cognition with evaluation of the intrinsic background gradients

Jahng GH, Xu S, Weiner MW, Meyerhoff DJ, Park S, Schuff N.

Neuroradiology. 2011 Oct;53(10):749-62. doi: 10.1007/s00234-011-0845-3. Epub 2011 Feb 22.

Inflammatory risk factors and pathologies associated with Alzheimer's disease

Sastre M, Richardson JC, Gentleman SM, Brooks DJ.

Curr Alzheimer Res. 2011 Mar;8(2):132-41. doi: 10.2174/156720511795256062.

Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies

Anstey KJ, Cherbuin N, Budge M, Young J.

Obes Rev. 2011 May;12(5):e426-37. doi: 10.1111/j.1467-789X.2010.00825.x. Epub 2011 Feb 23.

Sublingual sufentanil for incident pain and dementia-related response agitation

Passmore MJ.

Int Psychogeriatr. 2011 Jun;23(5):844-6. doi: 10.1017/S1041610211000275. Epub 2011 Feb 25.

Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study

Goveas JS, Espeland MA, Hogan P, Dotson V, Tarima S, Coker LH, Ockene J, Brunner R, Woods NF, Wassertheil-Smoller S, Kotchen JM, Resnick S.

J Affect Disord. 2011 Jul;132(1-2):275-84. doi: 10.1016/j.jad.2011.01.020. Epub 2011 Feb 24.

Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease

Honea RA, Swerdlow RH, Vidoni ED, Burns JM.

Neurology. 2011 Mar 1;76(9):822-9. doi: 10.1212/WNL.0b013e31820e7b74.

Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia

Walther S, Schüpbach B, Seifritz E, Homan P, Strik W.

J Clin Psychopharmacol. 2011 Apr;31(2):256-8. doi: 10.1097/JCP.0b013e31820e861c.

[Prenatal infection as driving force of aging-associated neurodegenerative diseases]

Knuesel I.

Praxis (Bern 1994). 2011 Mar 2;100(5):299-304. doi: 10.1024/1661-8157/a000451.

Anatomy of language impairments in primary progressive aphasia

Rogalski E, Cobia D, Harrison TM, Wieneke C, Thompson CK, Weintraub S, Mesulam MM.

J Neurosci. 2011 Mar 2;31(9):3344-50. doi: 10.1523/JNEUROSCI.5544-10.2011.

Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort

Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F; Medical Research Council Cognitive Function and Ageing Study.

Am J Epidemiol. 2011 May 1;173(9):1004-12. doi: 10.1093/aje/kwq476. Epub 2011 Mar 4.

Dementia and depression with ischemic heart disease: a population-based longitudinal study comparing interventional approaches to medical management

Mutch WA, Fransoo RR, Campbell BI, Chateau DG, Sirski M, Warrian RK.

PLoS One. 2011 Feb 28;6(2):e17457. doi: 10.1371/journal.pone.0017457.

A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes

Rohrer JD, Warren JD, Reiman D, Uphill J, Beck J, Collinge J, Rossor MN, Isaacs AM, Mead S.

J Neurol. 2011 Aug;258(8):1494-6. doi: 10.1007/s00415-011-5966-4. Epub 2011 Mar 9.

Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease

Rissman RA, Mobley WC.

J Neurochem. 2011 May;117(4):613-22. doi: 10.1111/j.1471-4159.2011.07237.x. Epub 2011 Mar 28.

Daytime sleepiness in mild Alzheimer's disease with and without parkinsonian features

Park M, Shah RC, Fogg LF, Wyatt JK.

Sleep Med. 2011 Apr;12(4):397-402. doi: 10.1016/j.sleep.2010.09.006.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias